[Diffuse toxic goiter].
Dedov II, Mel'nichenko GA, Aleksandrova GF.
Klin Med (Mosk). 1992 May-Jun;70(5-6):65-70.
[From diffuse goiter to nodular goiter].
Derwahl M.
Internist (Berl). 1998 Jun;39(6):577-83. doi: 10.1007/s001080050214.
[Peculiarities of formation, clinical presentations and therapy of diffuse nontoxic goiter of children].
Byriak VN, Murashko ES.
Lik Sprava. 2012 Apr-Jun;(3-4):31-5.
Thyroid-related ophthalmology.
Zobian J, Maus M.
Curr Opin Ophthalmol. 1998 Dec;9(6):105-10. doi: 10.1097/00055735-199812000-00019.
Diffuse nontoxic and multinodular goiter.
Nakhjavani M, Gharib H.
Curr Ther Endocrinol Metab. 1997;6:109-12.
Clinical-laboratory and ultrasound parallels of changes in the liver and thyroid gland in diffuse toxic goiter.
Lavruk KZ, Dudiy PF, Skrypnyk NV, Mishchuk VH, Vytvytskiy ZY.
J Med Life. 2022 Jan;15(1):78-88. doi: 10.25122/jml-2021-0291.
Nontoxic goiter-diffuse or nodular.
Maloof F, Wang CA, Vickery AL Jr.
Med Clin North Am. 1975 Sep;59(5):1221-32. doi: 10.1016/s0025-7125(16)31970-8.
[Role of diffuse nontoxic goiter in the structure of thyroid gland diseases in children].
Buriak VN, Nal'kovskaia LV.
Lik Sprava. 2006 Jan-Sep;(1-2):3-6.
Etiopathology, clinical features, and treatment of diffuse and multinodular nontoxic goiters.
Knobel M.
J Endocrinol Invest. 2016 Apr;39(4):357-73. doi: 10.1007/s40618-015-0391-7. Epub 2015 Sep 21.
Prediction factors for the risk of diffuse non-toxic goiter development in type 2 diabetic patients.
Musiienko V, Sverstiuk A, Lepyavko A, Mazur L, Danchak S, Lisnianska N.
Pol Merkur Lekarski. 2022 Apr 19;50(296):94-98.
